James McGorry tapped to lead HART of Holliston
COURTESY
James McGorry will be the next CEO of Holliston-based Harvard Apparatus Regenerative Technology (HART), the company announced today.
The statement said McGorry brings extensive management and commercialization experience in biologics, personalized medicine and device spaces. The appointment is effective July 6.
Tom McNaughton, chief financial officer, had been serving as interim CEO of HART.
McGorry has been a member of the company’s board of directors since February 2013. “Jim is the idea person to lead HART at this time,” the chairman of the board, John F. Kennedy, said in the statement.
Kennedy noted that McGorry spent 12 years in senior management roles at Genzyme, and led the commercial development and launch of innovative tissue-engineered products. “He also brings extensive experience in the fields of personalized medicine and medical devices. For the past two years, Jim has provided invaluable insights as a member of our board, and we expect that HART will benefit greatly from his dedicated guidance as CEO,” Kennedy said.
McGorry most recently served as an executive vice president at Hackensack, N.J.-based Champions Oncology, and previously was an executive vice president at Accellent. During his tenure at Genzyme, he held leadership positions across several therapeutic areas, including bio surgery, cardiac surgery, oncology and transplant. A former president of Clineffect Systems, an electronic medical records company, McGorry began his life sciences career with Baxter Healthcare Corp. He also was an officer in the Army for six years, including commanding a special operations Green Beret dive team.
HART develops regenerated organs for transplants needed in cases of cancer and other diseases, focusing on the trachea and esophagus. It spun off from Harvard Bioscience, of Holliston, in 2013.
“I’m eager to work more closely with the entire HART team to make bioengineered organs for the airways and esophagus available to patients,” McGorry said in the statement. “HART has the potential to change the way patients are treated with organ implants that the body integrates as its own.”
WBJ Web Partners
Most Recent
Most Recent
0 Comments